Brief: FDA Terms Amgen's Vectibix Promotional Video Misleading, Orders Ceasure Of Communications
Tue 18:29
BRIEF-FDA Terms Amgen's Vectibix Promotional Video Misleading, Orders Ceasure Of Communications Oct 27 (Reuters) - FDA:
FDA: AMGEN VECTIBIX PROMOTIONAL VIDEO FOUND FALSE OR MISLEADING - WEBSITE
FDA: AMGEN VECTIBIX VIDEO OMITS MATERIAL RISK INFORMATION INCLUDING DERMATOLOGIC TOXICITY, INFUSION REACTIONS, PULMONARY FIBROSIS
FDA: AMGEN ORDERED TO CEASE MISLEADING VECTIBIX PROMOTIONAL COMMUNICATIONS; FACES SEIZURE AND INJUNCTION IF VIOLATIONS NOT CORRECTED
Further company coverage: AMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amgen
See all newsFDA warns Amgen over cancer drug promotional video (updated)
Brief: FDA Terms Amgen's Vectibix Promotional Video Misleading, Orders Ceasure Of Communications
FDA warns Amgen over cancer drug promotional video
US RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer